logo-loader
viewZelira Therapeutics Ltd

Zelda Therapeutics making strides in medical cannabis research

Zelda continues to ramp up its clinical trial activities in Chile.

1505257491_medical-trial.jpg
Chile provides support for medical cannabis research

Zelda Therapeutics Ltd (ASX:ZLD) is making significant progress with its medical cannabis research program in Chile.

The company has already established a focus on autism, eczema and insomnia.

Zelda has now engaged the services of an experienced team of clinicians and scientists to help manage its clinical trials.

Harry Karelis, executive chairman, commented:

"We welcome Dr Kuester, Dr Sasso and Ms Vergara to our research team and are delighted to have such a high calibre local team coordinating our activities in Chile.

"Zelda is steadily progressing towards commencement of its clinical trial program in Chile and I look forward to providing shareholders positive updates in due course."

Why Chile

Zelda has strategically focused on conducting its research activities in Chile due to the efficiency of its legal and regulatory framework, cost effectiveness and its market access into the large South American pharmaceutical market.

The Chilean government granted permission for the first cannabis crop to be planted for medicinal purposes in 2015, and has subsequently allowed the sale of medicinal cannabis in pharmacies.

This has given rise to researchers and organisations specialising in medicinal cannabis treatments.

Zelda has capitalised on this, forming strategic alliances with world-class researchers and physicians, and has access to valuable patient data which will assist in the development of robust clinical trials.

Quick facts: Zelira Therapeutics Ltd

Price: 0.058 AUD

ASX:ZLD
Market: ASX
Market Cap: $56.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read